PET Imaging of Cannabinoid CB1 Receptors Using [11C]MePPEP

• Status: Completed
• Trial end date: 2013-01-22
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this protocol is to measure brain CB1 receptors in the hope to better understand how they work, so that one day we can understand how the CB1 receptors are involved in psychiatric, neurological, and behavioral disorders.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: National Institute of Mental Health (NIMH)

Criteria

• INCLUSION CRITERIA:

All subjects must be healthy and aged 18 65 years, with history/physical exam, ECG, and laboratory tests within one year of the PET scan. The volunteer must sign an informed consent form.

EXCLUSION CRITERIA:

• Current psychiatric illness, substance abuse including marijuana use, or severe systemic disease based on history and physical exam.

• Laboratory tests with clinically significant abnormalities or positive urine toxicology screen.

• Prior participation in other research protocols in the last year such that radiation exposure would exceed the annual limits.

• Pregnancy and breast feeding.

• Claustrophobia.

• Presence of ferromagnetic metal in the body or heart pacemaker.

• Positive HIV test.

• Employee of the investigative site or an immediate family member of an employee of the investigative site. Immediate family member is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.

• Employee of Eli Lilly and Company.